Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors

Double/triple-hit lymphomas (DHL/THL) account for 5–10% of diffuse large B cell lymphoma (DLBCL) with rearrangement of MYC and BCL2 and/or BCL6 resulting in MYC overexpression. Despite the poor prognosis of DHL, R-CHOP chemotherapy remains the treatment backbone and new targeted therapy is needed. W...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Weiping, Gupta, Shiv K., Han, Weiguo, Kundson, Ryan A., Nelson, Sara, Knutson, Darlene, Greipp, Patricia T., Elsawa, Sherine F., Sotomayor, Eduardo M., Gupta, Mamta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617630/
https://www.ncbi.nlm.nih.gov/pubmed/31288832
http://dx.doi.org/10.1186/s13045-019-0761-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617630/
https://www.ncbi.nlm.nih.gov/pubmed/31288832
http://dx.doi.org/10.1186/s13045-019-0761-2

Ejemplares similares